Lynx1 Capital Management LP

13D and 13G Filings

Investors who own more than 5% of a class must file a Schedule 13D or 13G. The latest filing for each security since 12/18/2024, newest first.

Issuer % of Class Filed
TScan Therapeutics, Inc. 13G/A
TCRX · 89854M101
 13.1% 8/14/2026
Event 6/30/2026
Stoke Therapeutics, Inc. 13G/A
STOK · 86150R107
 6.5% 8/14/2026
Event 6/30/2026
C4 Therapeutics, Inc. 13G/A
CCCC · 12529R107
 10.0% 8/14/2026
Event 6/30/2026
iBio, Inc. 13G
IBIO · 451033708
 5.4% 8/14/2026
Event 6/30/2026
GH Research PLC 13G/A
GHRS · G3855L106
 19.3% 8/14/2026
Event 6/30/2026
Precision Biosciences Inc 13G
DTIL · 74019P207
 5.4% 7/20/2026
Event 7/13/2026
Passage BIO, Inc. 13D
PASG · 702712100
 21.0% 7/2/2026
Event 6/25/2026
Allogene Therapeutics, Inc. 13G/A
ALLO · 019770106
 0% 5/15/2026
Event 12/31/2025
Agios Pharmaceuticals, Inc. 13G
AGIO · 00847X104
 5.1% 5/6/2026
Event 4/29/2026
Korro Bio, Inc. 13G/A
KRRO · 500946108
 10.7% 4/2/2026
Event 3/31/2026
Neuphoria Therapeutics Inc. 13D/A
NEUP · 64136E102
 16.3% 12/29/2025
Event 12/26/2025
Cullinan Therapeutics, Inc. 13G/A
CGEM · 230031106
 9.8% 11/14/2025
Event 9/30/2025